Jump Financial’s Y-mAbs Therapeutics YMAB Stock Holding History

Jump Financial’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-61,500	Closed	-$277K	–	2285
2025 Q2	$277K	Buy	61,500 +23,421	+62%	+$105K	﹤0.01%	1446
2025 Q1	$169K	Buy	38,079 +4,699	+14%	+$27.3K	﹤0.01%	1454
2024 Q4	$261K	Buy	+33,380	New	+$407K	0.01%	1377
2023 Q4	–	Sell	-18,800	Closed	-$102K	–	2322
2023 Q3	$102K	Sell	18,800 -20,887	-53%	-$122K	﹤0.01%	1673
2023 Q2	$269K	Sell	39,687 -1,213	-3%	-$9.09K	0.01%	1365
2023 Q1	$205K	Buy	+40,900	New	+$167K	0.01%	1309
2021 Q2	–	Sell	-11,800	Closed	-$357K	–	1431
2021 Q1	$357K	Buy	11,800 +7,379	+167%	+$303K	0.03%	540
2020 Q4	$219K	Buy	+4,421	New	+$204K	0.04%	738

Other funds holding YMAB

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jump Financial's YMAB Position: Q3 2025 in Review

Jump Financial sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 61,500 shares — an estimated $277K sold.

Jump Financial first reported a position in YMAB in Q4 2020 and held it in 8 quarters. The position peaked at $357K in Q1 2021. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

Jump Financial reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
Jump Financial sold 61,500 Y-mAbs Therapeutics shares in Q3 2025, an estimated $277K.
Jump Financial first reported a position in Y-mAbs Therapeutics in Q4 2020 and held it in 8 quarters.
Jump Financial's Y-mAbs Therapeutics position peaked at $357K in Q1 2021.
2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Jump Financial's 13F filing for Q3 2025, filed 13 Nov 2025.